[Skip to content]

You are here:   Home  »  About us  »  Departments and services  »  Breast Care  »  Research


The Breast Care team are involved with a number of clinical trials at any one time. We endeavour to offer relevant clinical trials to all patients who are eligible as this helps to improve the treatment for patients in future. If you are asked to consider participating in a trial or research study you will be given the approved information sheet or leaflet and time to make your decision. If you choose not to participate in a trial you will still be offered standard treatment.Our research portfolio is administered by our Research Nurse, Kaitlin Duckworth. If you have any queries, please do not hesitate to ask your clinical team.

The following list was correct at time of publication in mid-2019 but changes frequently: 

Current trials that are open to recruitment for breast at GH:

POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes.

Pre-Atnec- The primary aim of this study is to determine whether black ink tattoo injected into an axillary lymph node can be visualized intra-operatively in the same fashion blue sentinel nodes are identified. 

The second objective is to determine the concordance between tattooed, biopsied axillary lymph node and sentinel node.

The third objective is to compare the preoperative pathological assessment with the histological findings of resected nodes.     ( RECENTLY CLOSED TO RECRUITMENT PRIOR TO ATNEC)

LORIS- The LORIS Trial aims to establish whether patients with newly diagnosed low risk DCIS can safely avoid surgery without detriment to their wellbeing (psychological and physical) and whether those patients who do require surgery can be identified by pathological and radiological means.

EXPAT- Development and Application of Ex Vivo Assays to Assess Efficacy Biomarkers in the Prevention and Treatment of Cancer.

Breast trials ran from the Hope unit LRI: 

Add-Aspirin- A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

Impassion- A Phase III Randomised Study to Investigate the Efficacy and Safety of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer

VIOLETTE- A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2).

BYLieve- A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment.